

Rx Hepatitis B Vaccine (rDNA) IP

Revac-B[®]

1. NAME AND DESCRIPTION OF THE MEDICAL PRODUCT

Revac-B[®] is a sterile suspension containing purified, non-infectious major surface antigen of Hepatitis-B virus and is manufactured by recombinant DNA technology. The antigen is adsorbed onto high affinity aluminum hydroxide gel molecules and hence the suspension appears almost white and translucent.

Revac-B[®] fulfills WHO Requirements for Hepatitis-B Vaccine made by recombinant DNA techniques.

Recombinant Technology

The Hepatitis-B surface Antigen (HBsAg) is produced in genetically engineered yeast cells of *Pichia pastoris* which carry the gene that codes for the major surface antigen protein of the Hepatitis-B virus. HBsAg expressed in yeast cells is purified by complex physical, chemical and biochemical processes. The resultant highly purified surface antigen assembles spontaneously into spherical particles of an average diameter of 20-24nm containing non-glycosylated polypeptides in a lipid matrix. An extensive and rigorous R&D process characterised and confirmed that these 20-24nm spherical particles resemble the natural HBsAg protein in their antigenic properties. The efficacy and safety of the formulated **Revac-B[®]** is ensured through stringent adherence to the highest standards of bio-process control and consistent Quality Assurance measures. **No substance of Human origin is used in the manufacture of HBsAg protein.**

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

a) Composition: Each pediatric dose of 0.5 mL contains

Hepatitis B surface Antigen (HBsAg)	≥10 µg
Aluminumhydroxide gel equivalent to Aluminum (Al ⁺⁺⁺)	0.25 mg
Thiomersal IP	0.025 mg
Phosphate buffered saline	q.s to 0.5 mL.

b) Composition: Each adult dose of 1.0 mL contains

Hepatitis B surface Antigen (HBsAg)	≥20 µg
Aluminumhydroxide gel equivalent to Aluminum (Al ⁺⁺⁺)	0.5 mg
Thiomersal IP	0.05 mg
Phosphate buffered saline	q.s to 1.0 mL.

3. PHARMACEUTICAL FORM:

Suspension for injection

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

Revac-B[®] is indicated for immunoprotection of persons against infection by Hepatitis B virus and its common sub types. It can also be administered to hepatitis C and D virus infected patients to protect them against co-infection with hepatitis B virus.

Revac-B[®] is recommended primarily for neonates, infants and young adults not only for the prevention of the disease but also to protect them from probable hepatitis B virus-induced carrier state, cirrhosis and hepatocellular carcinoma. In addition, for various groups of individuals as listed below **Revac-B[®]** immunization is an essential requirement:

- Healthcare personnel
- Patients prone to infection due to unscreened or improperly tested blood transfusions
- Hemophiliacs and patients on hemodialysis.
- Travelers to specified high endemic areas.
- Residents in high endemic areas.
- Persons in contact with infected sexual partners.
- Drug addicts
- Personnel and residents of community homes or hostels
- Household contacts of persons with acute or chronic HBV infection
- Infants born to HBV carrier mothers.
- Organ transplant recipients
- Others/Police, armed forces and such other these 20-24nm spherical particles resemble the natural HBsAg protein in their antigenic properties.

4.2 Posology, Schedule and Method of Administration

20µg/0.5mL is the dose for adult and children above 10 years of age.

10µg/0.5mL is recommended for neonates, infants and children below 10 years of age.

4.3 Primary immunization schedule:

Indian Academy of Pediatrics recommends as follows for children:

- At Birth
- At 6 weeks of age
- At 6 months. The final (3rd or 4th) dose administered no earlier than age 24 weeks and at least 16 weeks after the first dose.

As per Universal Immunisation Program, hepatitis B vaccine is provided as part of pentavalent vaccine at 6, 10 & 14 weeks apart from birth dose.

Adults: An interval of 30 days given between the administration of the FIRST and SECOND doses, followed by the THIRD dose 180 days after the first dose.

B. Special recommendations:

- To neonates born to HBV infected mothers the recommended pediatric dose schedule:

- 1 dose on selected date
- 2 dose 30 days after the first dose
- 3 dose 90 days after the first dose

- One booster dose to be administered 1 year after the first dose

Hepatitis B immunoglobulins may also be given to comprised neonates on advice from medical practitioner.

- To persons involuntarily exposed by accident to HBV infection:
 - The schedule of immunization stated above is recommended at pediatric dose level for children and as adult dose for others.
 - Immuno-compromised patients will require additional dose as per schedule given:
 - 1 dose of 40µg/2mL on the first day
 - 2 dose of 40µg/2mL, 30 days after the first dose
 - 3 dose of 40µg/2mL, 60 days after the first dose
 - 4 dose of 40µg/2mL, 180 days after the first dose

C. Method of Administration

Revac-B[®] should be injected deep intramuscularly into the deltoid region in adults and in the Antero-lateral aspect of thigh in neonates, infants and young children.

Revac-B[®] should NOT be injected into the gluteal muscle. This route of administration may result in lower immune response. Under no circumstance **Revac-B[®]** should be given intravenously.

4.3 Contraindications

Revac-B[®] is generally well tolerated. However, the vaccine should not be administered or repeated to persons known to be hypersensitive to any of the components of the vaccine. Avoid immunization during severe febrile illness.

4.4 Special Warning/Precautions

- Do not administer intravenously, intradermally, or subcutaneously.
- Like all other vaccines, supervision and appropriate medical treatment should always be available to treat any anaphylactic reactions following immunization.
- Epinephrine injection (1:1000) must be immediately available in case of an acute anaphylactic reaction or any allergic reaction occurs due to any component of the vaccine.
- The vaccine should remain under medical supervision for at least 30 minutes after vaccination.

While using the multi-dose vial, care must be taken to use separate sterile syringe and needle for the administration of every dose. Used multi-dose vial that contains remaining vaccine must be stored at the recommended storage temperature and reexamined carefully prior to reuse. A multi-dose vial of

Revac-B[®] from which one or more doses of vaccine have been removed during an immunization session may be used in subsequent immunization sessions for up to maximum of 4 weeks, provided that all the following conditions are met:

- The expiry date has not passed
- The vaccines are stored under appropriate cold chain conditions
- The vaccine vial septum has not been submerged in water
- Aseptic technique has been used to withdraw all doses.

Before use, **Revac-B[®]** should be well shaken to obtain a uniform, whitish translucent suspension. Vial should be visually checked for the presence of any particulate matter or other coloration, if any prior to its administration. If in doubt, do not use the contents of the vial.

Revac-B[®] can be administered at the same time as BCG, DTP/OPV and measles vaccines that are contained in the Universal Immunization Program (UIP). **Revac-B[®]** should always administered at a different injection site in the event of its use along with UIP vaccines.

Revac-B[®] should NOT be mixed with other vaccines.

NOTE: Because of the long incubation for hepatitis-B virus to manifest the symptoms, some subjects may receive the vaccine while infection stays unrecognized. In such cases, the vaccine may not prevent the onset of hepatitis due to hepatitis-B virus.

Revac-B[®] will not prevent hepatitis caused by other viruses such as hepatitis A, hepatitis C and hepatitis D and other agents known to infect liver.

4.5 Interactions with Other Medicinal Products

The simultaneous administration of **Revac-B[®]** and a standard dose of HepB Ig does not result in lower anti-HBs antibody concentrations provided that they are administered at separate injection sites.

Revac-B[®] can be given concomitantly with Haemophilus influenzae type b, BCG, hepatitis A, polio, measles, mumps, rubella, diphtheria, tetanus and pertussis vaccines, human papillomavirus (HPV) Different injectable vaccines should always be administered at different injection sites.

Revac-B[®] may be used to complete a primary immunisation course started either with plasma-derived or with genetically-engineered hepatitis B vaccines, or, if it is desired to administer a booster dose, may be administered to subjects who received a primary immunisation course with plasma-derived or with genetically-engineered hepatitis B vaccines

4.6 Pregnancy and Lactation

Routine vaccination of pregnant women with recombinant Hepatitis-B vaccine is not recommended due to inadequate data on its effects on the foetus. No contraindication was recorded for the use of the vaccine in lactating mothers. However, the decision to immunize pregnant and lactating mothers may be taken by the physician in the context of case specific high-risk factors.

4.7 Effects on Ability to Drive and Use Machines

No studies on the effect of **Revac-B[®]** on the ability to drive and use machines have been performed.

4.8 Adverse Reactions

Revac-B[®] is well tolerated.

Inflammation at the site of injection or a febrile reaction may be observed in some subjects. In rare cases of post-vaccinal hypersensitivity, the common symptoms that are quickly recognized by the physician are dizziness, headache, nausea, abdominal pain, rash, pruritis, urticaria, arthralgia, myalgias and similar associated symptoms and side effects.

4.9 Pre-Clinical & Clinical Trial Experience

A 60-day repeat-dose non-clinical toxicity study in mice and guinea pigs were conducted to establish immunogenicity in the chronic toxicity of hepatitis B vaccine in mice and guinea pigs after administration of the vaccine by intramuscular route on day 0, 7, and 14th day. Food consumption, body weight, biochemistry, hematology parameters were estimated and all parameters normal. No detectable signs of pain, edema or inflammation were observed at site of injections based on the results, **Revac-B[®]** was safe at the doses used in chronic toxicity study in mice and guinea pigs.

A phase 3 clinical trial was conducted to study the reactivity and immunogenicity of yeast derived Hepatitis B vaccine in 196 healthy adults. Blood samples were collected and immunogenicity was tested on Day 30, 90 and 180 and **Revac-B[®]** was safe & immunogenic comparable to other commercial vaccine.

An multi-center post marketing surveillance was conducted to establish the safety of **Revac-B[®]** produced in Pichia pastoris in 1185 subjects aged from less than 1 month to about 70 years. The adverse events commonly seen were minor local reactions, such as pain at the site of injection, pruritis and systemic reactions like fever (3.2%) within levels observed in similar studies earlier. This study thus conclusively establishes that the recombinant Hepatitis B vaccine, **Revac-B[®]** produced in Pichia pastoris is safe, all age groups including neonates. No unexpected adverse vaccine reactions were observed during the study.

A post-marketing study was conducted to evaluate safety and boosting effect in children receiving one booster dose of **Revac-B[®]** in subjects aged between 5 and 6 years. Serum samples were subjected to ELISA tests (AUSAB) and the titers were expressed as mIU/mL. An increase in the antibody titers from less than 10 mIU/mL to a value >10mIU/mL was considered to be seroconverted. A four-fold increase in the titer was considered significant. A titer of children above 10 mIU/mL is considered seroprotective. No unexpected or untoward reactions have been reported.

Another post-marketing study was conducted to evaluate safety and immunogenicity in infants receiving their first two doses of **Revac-B[®]** on day 1 and day 30 in 282 subjects, aged between 3 and 6 months (single administration). The mean titer value increased from 0.47 mIU/mL in the first sample to 155.24 mIU/mL. The phase 4 study in infants proved the immunogenicity of **Revac-B[®]** as high as 99% seroconversion, 2% of subjects showed local reactions during the study. The results conclusively establish that the recombinant Hepatitis B vaccine, **Revac-B[®]** produced in Pichia pastoris by Bharat Biotech is safe and immunogenic in children and adults.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties: Not Applicable

5.2 Pharmacokinetic Properties: Evaluation of pharmacokinetic properties is not required for vaccines.

6. PHARMACEUTICAL PARTICULARS:

6.1 List of Excipients

- Aluminumhydroxide gel equivalent to Aluminum (Al⁺⁺⁺)
- Thiomersal IP
- Phosphate buffered saline

6.2 Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf Life: The expiry date of the vaccine is indicated on the label and carton of the product.

6.4 Storage: Store at +2°C to +8°C. Shake well before use. Do not freeze. Discard if frozen. Keep out of reach of children.

7. PRESENTATION: Revac-B[®] is presented in USP type 1 glass vial. The content on storage may separate into a fine white suspension. It is well supersaturated. Once shaken the vaccine is slightly opaque.

Paediatric Single dose: 0.5 mL

Paediatric Multi dose: 2.5 mL

Paediatric Multi dose: 5 mL

Adult Single dose: 1 mL

Adult Multi dose: 10 mL

8. SAFETY, STABILITY AND POTENCY **Revac-B[®]** contains highly purified HbsAg in a formulation that consistently conforms to pharmaceutical standards.

Experimental data both at the production and R&D laboratories, have shown the formulation to be stable and potent for 36 months at +2°C to +8°C

Exposure of vaccine to higher temperature at 37°C for 1 month & 45°C for 1 week did not result in the loss of its immunogenicity.

Last revision date: July 2018

Manufactured & Marketed by:



Lead Scientist

Bharat Biotech International Ltd.,

Genome Valley, Shanmugampal, Medchal District - 500 078, Telangana, India.

www.bharatbiotech.com. For complaints and suggestions.

For complaints and suggestions about the product, and any adverse event.

please email feedback@bharatbiotech.com or call on toll free number 1800 102 1245